ADIL (Adial Pharmaceuticals) EPS (Basic) : $-4.31 (TTM As of Sep. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Adial Pharmaceuticals EPS (Basic)?

Adial Pharmaceuticals's basic earnings per share (Basic EPS) for the three months ended in Sep. 2024 was $-0.38. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Sep. 2024 was $-4.31.

Adial Pharmaceuticals's EPS (Diluted) for the three months ended in Sep. 2024 was $-0.38. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $-4.31.

Adial Pharmaceuticals's EPS without NRI for the three months ended in Sep. 2024 was $-0.38. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2024 was -2.79.

During the past 3 years, the average EPS without NRI Growth Rate was 39.10% per year. During the past 5 years, the average EPS without NRI Growth Rate was 30.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 9 years, Adial Pharmaceuticals's highest 3-Year average EPS without NRI Growth Rate was 39.10% per year. The lowest was -110.90% per year. And the median was -21.55% per year.

Adial Pharmaceuticals EPS (Basic) Historical Data

The historical data trend for Adial Pharmaceuticals's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adial Pharmaceuticals EPS (Basic) Chart

Adial Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EPS (Basic)

Get a 7-Day Free Trial

-21.75

-26.00

-12.71

-3.60

Adial Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EPS (Basic)	Get a 7-Day Free Trial															-1.18	-1.15	-2.19	-0.59	-0.38

Adial Pharmaceuticals EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Adial Pharmaceuticals's Basic EPS for the fiscal year that ended in Dec. 2023 is calculated as

Basic EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-5.123	-	0)	/	1.425
	=	-3.60

Adial Pharmaceuticals's Basic EPS for the quarter that ended in Sep. 2024 is calculated as

Basic EPS (Q: Sep. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-2.192	-	0)	/	5.836
	=	-0.38

EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.31

Adial Pharmaceuticals (NAS:ADIL) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Adial Pharmaceuticals EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Adial Pharmaceuticals's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Adial Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adial Pharmaceuticals Inc (NAS:ADIL) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

N/A

Address

4870 Sadler Road, Suite 300, Glen Allen, VA, USA, 23060

Website

https://www.adialpharma.com

Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist.

Executives

Kevin Schuyler	director	1180 SEMINOLE TRAIL, SUITE 495, CHARLOTTESVILLE VA 22901
Stilley William B. Iii	director, 10 percent owner, officer: Chief Executive Officer	1180 SEMINOLE TRAIL, SUITE 495, CHARLOTTESVILLE VA 22901
Newman James W. Jr.	director	1180 SEMINOLE TRAIL, SUITE 495, CHARLOTTESVILLE VA 22901
Cary J Claiborne	director	3056 SENECA CHIEF TRAIL, ELLICOTT CITY MD 21042
Bankole A. Johnson	director, 10 percent owner	1180 SEMINOLE TRAIL, SUITE 495, CHARLOTTESVILLE VA 22901
Jack W Reich	director	C/O COLLATERAL THERAPEUTICS, 11622 EL CAMINO REAL, SAN DIEGO CA 92130
Tony Goodman	director	1180 SEMINOLE TRAIL, SUITE 495, CHARLOTTESVILLE VA 22901
J. Kermit Anderson	director	1180 SEMINOLE TRAIL, SUITE 495, CHARLOTTESVILLE VA 22901
Joseph Truluck	officer: COO and CFO	1180 SEMINOLE TRAIL, SUITE 495, CHARLOTTESVILLE VA 22901
Robertson H. Gilliland	director	1180 SEMINOLE TRAIL, SUITE 495, CHARLOTTESVILLE VA 22901
En Fidecomiso De Mi Vida 11/23/2010 Trust	10 percent owner	11024 GAITHER FARM ROAD, ELLICOTT CITY MD 21042